Collective Family Office’s Takeda Pharmaceutical TAK Stock Holding History

Collective Family Office’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-21,050	Closed	-$354K	–	177
2021 Q2	$354K	Sell	21,050 -8,750	-29%	-$149K	0.15%	127
2021 Q1	$544K	Buy	+29,800	New	+$536K	0.27%	96

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Collective Family Office's TAK Position: Q3 2021 in Review

Collective Family Office sold out of Takeda Pharmaceutical (TAK) in Q3 2021, closing a stake of 21,050 shares — an estimated $354K sold.

Collective Family Office first reported a position in TAK in Q1 2021 and held it in 2 quarters. The position peaked at $544K in Q1 2021. 292 funds tracked by Wall St. Rank hold TAK as of Q3 2021.

Collective Family Office reported no remaining Takeda Pharmaceutical position as of Q3 2021 after selling out during the quarter.
Collective Family Office sold 21,050 Takeda Pharmaceutical shares in Q3 2021, an estimated $354K.
Collective Family Office first reported a position in Takeda Pharmaceutical in Q1 2021 and held it in 2 quarters.
Collective Family Office's Takeda Pharmaceutical position peaked at $544K in Q1 2021.
292 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2021.

Based on Collective Family Office's 13F filing for Q3 2021, filed 8 Oct 2021.